Recap: ClearPoint Neuro Q3 Earnings

Shares of ClearPoint Neuro CLPT rose 9.49% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 12.50% year over year to ($0.09), which beat the estimate of ($0.14).

Revenue of $3,519,000 higher by 20.23% year over year, which beat the estimate of $2,470,000.

Guidance

ClearPoint Neuro hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Nov 10, 2020

Time: 04:30 PM

ET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/mric/mediaframe/41425/indexl.html

Price Action

Company's 52-week high was at $8.91

Company's 52-week low was at $2.86

Price action over last quarter: Up 92.07%

Company Profile

ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. It has two product platforms: ClearPoint system, which is in commercial use in the United States, is used to perform minimally invasive surgical procedures in the brain and ClearTrace system, which is under development, to be used to perform minimally invasive surgical procedures in the heart. The company's products and product candidates include ClearPoint neuro system, MRI-guided drug delivery, and Thermal therapy system.